Breakpoints cover image

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials

Breakpoints

00:00

C Diff - What's Next?

World AIDS Day today, I think it's a wonderful time to discuss and acknowledge these studies. Yesterday we got an FDA approval for a third agent by our friends at Faring Pharmaceuticals for the first microbiome product in C diff. And so this also feels quite timely to have this discussion. Now we're going to learn about six antibacterial agents in the pipeline.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app